Skip to Main Content

Paper Details

Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.
J Urol
24
2022
Author NameAffiliation
Tarek A BismarUniversity of Calgary, Cumming School of Medicine
Elai DavicioniVeracyte Inc.
Jonathan L WrightUniversity of Washington School of Medicine, Fred Hutchinson Cancer Research Center
  • 1 - 3

Datasets

Release 1.2